Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis.

Literature DB >> 28346855

TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis.

Christine C Krieger¹, Susanne Neumann¹, Bernice Marcus-Samuels¹, Marvin C Gershengorn¹.

Abstract

Entities: Disease Gene

Year: 2017 PMID： 28346855 PMCID： PMC5421635 DOI： 10.1089/thy.2017.0105

Source DB: PubMed Journal: Thyroid ISSN： 1050-7256 Impact factor: 6.568

× No keyword cloud information.

4 in total

1. A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells.

Authors: Christine C Krieger; Marvin C Gershengorn
Journal: Endocrinology Date: 2013-12-03 Impact factor: 4.736

2. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.

Authors: Christine C Krieger; Robert F Place; Carmine Bevilacqua; Bernice Marcus-Samuels; Brent S Abel; Monica C Skarulis; George J Kahaly; Susanne Neumann; Marvin C Gershengorn
Journal: J Clin Endocrinol Metab Date: 2016-04-04 Impact factor: 5.958

3. How IGF-1 activates its receptor.

Authors: Jennifer M Kavran; Jacqueline M McCabe; Patrick O Byrne; Mary Katherine Connacher; Zhihong Wang; Alexander Ramek; Sarvenaz Sarabipour; Yibing Shan; David E Shaw; Kalina Hristova; Philip A Cole; Daniel J Leahy
Journal: Elife Date: 2014-09-25 Impact factor: 8.140

Review 4. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.

Authors: Terry J Smith; Joseph A M J L Janssen
Journal: Front Endocrinol (Lausanne) Date: 2017-01-03 Impact factor: 5.555

4 in total

14 in total

1. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.

Authors: Susanne Neumann; Christine C Krieger; Marvin C Gershengorn
Journal: Eur Thyroid J Date: 2020-11-02

2. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.

Authors: Christine C Krieger; Alisa Boutin; Daesong Jang; Sarah J Morgan; J Paul Banga; George J Kahaly; Joanna Klubo-Gwiezdzinska; Susanne Neumann; Marvin C Gershengorn
Journal: Endocrinology Date: 2019-06-01 Impact factor: 4.736

3. Rebuttal to Smith and Janssen (Thyroid 2017;27:746-747. DOI: 10.1089/thy.2017.0281).

Authors: Susanne Neumann; Marvin C Gershengorn
Journal: Thyroid Date: 2017-10-17 Impact factor: 6.568

4. Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747).

Authors: Terry J Smith; Joseph A M J L Janssen
Journal: Thyroid Date: 2017-09-28 Impact factor: 6.568

TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis.

1. A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells.

2. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.

3. How IGF-1 activates its receptor.

Review 4. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy.

1. Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.

2. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.

3. Rebuttal to Smith and Janssen (Thyroid 2017;27:746-747. DOI: 10.1089/thy.2017.0281).

4. Response to Krieger et al. re: "TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis" (Thyroid 2017;27:746-747).

5. Modulating TSH Receptor Signaling for Therapeutic Benefit.

6. Thyroid Stimulating Hormone (TSH)/Insulin-like Growth Factor 1 (IGF1) Receptor Cross-talk in Human Cells.

7. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.

Review 8. TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.

9. Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors.

10. Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy.